MA31872B1 - Inhibiteurs de kinésine en tant que produits thérapeutiques anti-cancers - Google Patents

Inhibiteurs de kinésine en tant que produits thérapeutiques anti-cancers

Info

Publication number
MA31872B1
MA31872B1 MA32879A MA32879A MA31872B1 MA 31872 B1 MA31872 B1 MA 31872B1 MA 32879 A MA32879 A MA 32879A MA 32879 A MA32879 A MA 32879A MA 31872 B1 MA31872 B1 MA 31872B1
Authority
MA
Morocco
Prior art keywords
compounds
cancers
ksp
novel
inhibitors
Prior art date
Application number
MA32879A
Other languages
Arabic (ar)
English (en)
Inventor
Tinya Abrams
Paul Barsanti
David Duhl
Michel Faure
Paul A Renhowe
Annette Olga Walter
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40328566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31872(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31872B1 publication Critical patent/MA31872B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur de nouveaux composés imidazoles qui inhibent l'activité de protéine du fuseau kinésine (ksp, également appelée eg5). Des inhibiteurs de ksp peuvent réduire une prolifération cellulaire non souhaitée et fournir d'autres effets thérapeutiques. L'invention porte également sur des compositions pharmaceutiques contenant ces nouveaux composés, et sur des procédés d'utilisation des nouveaux inhibiteurs de ksp et de leurs compositions pharmaceutiques pour traiter divers types de cancers. Les composés, compositions et procédés de l'invention sont particulièrement utiles pour traiter certaines classes de cancers qui sont résistants à des traitements par les médicaments classiques, en raison du fait qu'il a été démontré que de tels cancers restent sensibles aux composés de l'invention.
MA32879A 2007-12-14 2010-05-31 Inhibiteurs de kinésine en tant que produits thérapeutiques anti-cancers MA31872B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1396607P 2007-12-14 2007-12-14
PCT/EP2008/067412 WO2009077448A1 (fr) 2007-12-14 2008-12-12 Inhibiteurs de kinésine en tant que produits thérapeutiques anti-cancers

Publications (1)

Publication Number Publication Date
MA31872B1 true MA31872B1 (fr) 2010-11-01

Family

ID=40328566

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32879A MA31872B1 (fr) 2007-12-14 2010-05-31 Inhibiteurs de kinésine en tant que produits thérapeutiques anti-cancers

Country Status (30)

Country Link
US (2) US8252832B2 (fr)
EP (1) EP2229170B1 (fr)
JP (1) JP5501976B2 (fr)
KR (1) KR20100098394A (fr)
CN (1) CN101939005B (fr)
AR (1) AR069676A1 (fr)
AU (1) AU2008337570B2 (fr)
BR (1) BRPI0821248A2 (fr)
CA (1) CA2708822A1 (fr)
CL (1) CL2008003707A1 (fr)
CO (1) CO6290651A2 (fr)
CR (1) CR11412A (fr)
DO (1) DOP2010000175A (fr)
EA (1) EA018014B1 (fr)
EC (1) ECSP10010248A (fr)
ES (1) ES2459442T3 (fr)
GE (1) GEP20125647B (fr)
GT (1) GT201000172A (fr)
IL (1) IL205831A0 (fr)
MA (1) MA31872B1 (fr)
MY (1) MY150214A (fr)
NI (1) NI201000091A (fr)
NZ (1) NZ585142A (fr)
PA (1) PA8807801A1 (fr)
PE (1) PE20091451A1 (fr)
SM (1) SMP201000095B (fr)
TN (1) TN2010000204A1 (fr)
TW (1) TW200930704A (fr)
UY (1) UY31532A1 (fr)
WO (1) WO2009077448A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
WO2011128388A2 (fr) * 2010-04-15 2011-10-20 Novartis Ag Composés d'oxazole et de thiazole comme inhibiteurs de ksp
WO2014151030A1 (fr) * 2013-03-15 2014-09-25 Novartis Ag Inhibiteurs de la prolifération cellulaire et leurs conjugués
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
WO2016020791A1 (fr) 2014-08-05 2016-02-11 Novartis Ag Conjugués anticorps ckit-médicament
CN108025084B (zh) * 2015-06-22 2024-08-09 拜耳医药股份有限公司 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc）
CN105418527A (zh) * 2015-12-28 2016-03-23 青岛友诚高新技术有限公司 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途
CN105646361B (zh) * 2016-02-17 2017-12-01 吉首大学 一种2,4,5‑三芳基咪唑型化合物及其制法和用途
EP3558388A1 (fr) 2016-12-21 2019-10-30 Bayer Pharma Aktiengesellschaft Conjugués liant-principe actif (adc) ayant des groupes enzymatiquement clivables
CN106668863B (zh) * 2017-02-21 2019-04-23 南方医科大学 靶向ktn1治疗皮肤鳞状细胞癌的药物
GB201706162D0 (en) * 2017-04-19 2017-05-31 Nat Univ Singapore Compounds
WO2019196111A1 (fr) * 2018-04-13 2019-10-17 上海交通大学医学院附属瑞金医院 Composé de type amide d'hétéroaryle utilisable contre les tumeurs multirésistantes aux médicaments anticancéreux, utilisation dans le traitement de cancers, et complexe moléculaire protéine-médicament
CN109646679A (zh) * 2019-01-28 2019-04-19 中国科学院长春应用化学研究所 铁离子螯合剂及其可药用盐的用途
CN111529526B (zh) * 2020-04-14 2021-04-23 广州领晟医疗科技有限公司 一种化合物在制备治疗急性胰腺炎的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06014909A (es) * 2004-06-18 2007-02-28 Chiron Corp Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
MY147188A (en) 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
WO2008086122A2 (fr) 2007-01-05 2008-07-17 Novartis Ag Dérivés cyclisés en tant qu'inhibiteurs d'eg-5

Also Published As

Publication number Publication date
EA201000900A1 (ru) 2011-02-28
MY150214A (en) 2013-12-13
PE20091451A1 (es) 2009-10-19
ES2459442T3 (es) 2014-05-09
CN101939005B (zh) 2015-12-16
CN101939005A (zh) 2011-01-05
US20090239922A1 (en) 2009-09-24
US8252832B2 (en) 2012-08-28
WO2009077448A1 (fr) 2009-06-25
ECSP10010248A (es) 2010-07-30
US20130012560A1 (en) 2013-01-10
TW200930704A (en) 2009-07-16
KR20100098394A (ko) 2010-09-06
SMAP201000095A (it) 2010-09-10
CA2708822A1 (fr) 2009-06-25
US8664256B2 (en) 2014-03-04
JP2011506402A (ja) 2011-03-03
DOP2010000175A (es) 2010-06-30
EP2229170B1 (fr) 2014-01-22
JP5501976B2 (ja) 2014-05-28
SMP201000095B (it) 2011-09-09
CR11412A (es) 2010-06-30
TN2010000204A1 (en) 2011-11-11
NI201000091A (es) 2011-03-15
AU2008337570A1 (en) 2009-06-25
EA018014B1 (ru) 2013-04-30
UY31532A1 (es) 2009-08-03
GT201000172A (es) 2012-04-30
AR069676A1 (es) 2010-02-10
PA8807801A1 (es) 2009-07-23
CO6290651A2 (es) 2011-06-20
EP2229170A1 (fr) 2010-09-22
AU2008337570B2 (en) 2012-04-05
NZ585142A (en) 2012-03-30
CL2008003707A1 (es) 2009-06-05
BRPI0821248A2 (pt) 2015-06-16
GEP20125647B (en) 2012-09-25
IL205831A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
MA31872B1 (fr) Inhibiteurs de kinésine en tant que produits thérapeutiques anti-cancers
Corazzari et al. Endoplasmic reticulum stress, unfolded protein response, and cancer cell fate
Harrach et al. Role of transporters in the distribution of platinum-based drugs
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA27937A1 (fr) Dérivés d'indazole 3, 5-disubstitués, compositions pharmaceutiques, et méthodes de médiation ou d'inhibition de la prolifération cellulaire
MA33075B1 (fr) Composition destinee a la regulation du metabolism des lipides
BRPI0518315B8 (pt) compostos de tiazol que modulam a atividade da proteína hsp90, métodos de inibição, tratamento e indução associados e composição farmacêutica
MA38099B1 (fr) Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
MA34909B1 (fr) Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vih
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
WO2019133770A3 (fr) Inhibiteurs de glycolate oxydase pour le traitement de maladies
TN2009000033A1 (fr) Derives de pyrazole servant d'inhibiteurs du cytochrome p450
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
WO2012171015A3 (fr) Combinaison thérapeutique pour un traitement anticancéreux
DE602005012069D1 (de) Inhibitoren von mitotischem kinesin
MA46229A (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
EP3128996B1 (fr) Nouveux dérivés de 7-déshydrocholestérol et procédés les utilisant
WO2022256714A3 (fr) Compositions d'édition de génome et méthodes de traitement de la maladie de wilson
TW200512198A (en) 5-arylpyrimidines as anticancer agents
MA44965B1 (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
BRPI0512832A (pt) composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para usar um composto
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle
Arora et al. System biology approach to identify potential receptor for targeting cancer and biomolecular interaction studies of indole [2, 1-a] isoquinoline derivative as anticancerous drug candidate against it